DiaMedica Therapeutics Inc

DMAC is in a Stage 4 decline despite a long-term uptrend, with a dominant lower high/low structure driving medium-term bearish bias. Price rallies have been rejected at declining EMAs and the 50-DMA, indicating supply control. A short-term uptick above EMAs reduces immediate sell timing, suggesting deferred execution. Trimming into resistance zones aligns with structural downtrend while awaiting clearer follow-through.

• ↑Phase 2 preeclampsia trial interim shows on-target mechanistic response.
• ↑Cash increased to $59.9 M, funding operations through 2027.
• ↓Net cash used jumped to $29.1 M in FY 2025, cutting runway to Q3 2026.